Indication
Dandruff
Dandruff, clinically referred to as pityriasis capitis, is a common, chronic, non-inflammatory scalp condition positioned at the mildest end of the seborrheic dermatitis spectrum. Read more about Dandruff
191 drugs 83 manufacturers
Drugs that treat it
Common Dandruff therapies.
SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM
OVACE PLUS (sulfacetamide sodium)
THERAPEUTIC SHAMPOO (coal tar)
THERAPEUTIC SHAMPOO (coal tar)
OVACE PLUS (sulfacetamide sodium)
SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonDandruff, clinically referred to as pityriasis capitis, is a common, chronic, non-inflammatory scalp condition positioned at the mildest end of the seborrheic dermatitis spectrum.
It primarily affects adolescents and adults, typically emerging post-puberty in hair-bearing regions of the scalp with active sebaceous glands.
Pathophysiologically, the condition is driven by epidermal barrier dysfunction, sebaceous lipid secretion, and an individual cutaneous response to metabolites produced by commensal *Malassezia* yeasts.
These mechanisms accelerate epidermal proliferation and turnover, producing defining clinical features of diffuse, uninflamed desquamation characterized by visible white-to-gray flakes, often accompanied by mild pruritus without marked erythema.
- nih.gov
Dandruff, clinically referred to as pityriasis capitis, is a common, chronic, non-inflammatory scalp condition positioned at the mildest end of the seborrheic dermatitis spectrum These mechanisms accelerate epidermal proliferation and turnover, producing defining clinical features of diffuse, uninflamed desquamation characterized by visible white-to-gray flakes, often accompanied by mild pruritus without marked erythema
- dermnetnz.org
Dandruff, clinically referred to as pityriasis capitis, is a common, chronic, non-inflammatory scalp condition positioned at the mildest end of the seborrheic dermatitis spectrum It primarily affects adolescents and adults, typically emerging post-puberty in hair-bearing regions of the scalp with active sebaceous glands These mechanisms accelerate epidermal proliferation and turnover, producing defining clinical features of diffuse, uninflamed desquamation characterized by visible white-to-gray ...
- nih.gov
It primarily affects adolescents and adults, typically emerging post-puberty in hair-bearing regions of the scalp with active sebaceous glands These mechanisms accelerate epidermal proliferation and turnover, producing defining clinical features of diffuse, uninflamed desquamation characterized by visible white-to-gray flakes, often accompanied by mild pruritus without marked erythema
- wikipedia.org
It primarily affects adolescents and adults, typically emerging post-puberty in hair-bearing regions of the scalp with active sebaceous glands
- nih.gov
Pathophysiologically, the condition is driven by epidermal barrier dysfunction, sebaceous lipid secretion, and an individual cutaneous response to metabolites produced by commensal *Malassezia* yeasts
- nih.gov
Pathophysiologically, the condition is driven by epidermal barrier dysfunction, sebaceous lipid secretion, and an individual cutaneous response to metabolites produced by commensal *Malassezia* yeasts
- nih.gov
Pathophysiologically, the condition is driven by epidermal barrier dysfunction, sebaceous lipid secretion, and an individual cutaneous response to metabolites produced by commensal *Malassezia* yeasts
Personalize your experience
Follow Dandruff and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.